ASCO 2026 Lifts Embargo on 7,000+ Abstracts — BREAKWATER, VIKTORIA-1, EV-302 Phase 3 Data Unlocked

At 5:00 PM ET on May 21, 2026, the American Society of Clinical Oncology (ASCO) lifted the embargo on over 7,000 abstracts for the 2026 Annual Meeting (May 29 – June 2, McCormick Place, Chicago) — the largest abstract volume in ASCO history, selected from a record 8,700 submissions. Key late-breaking datasets now in public discourse ahead of the plenary session: (1) BREAKWATER trial: BRAFTOVI (encorafenib) + cetuximab + FOLFIRI as first-line therapy for BRAF V600E-mutant metastatic colorectal cancer — progression-free and overall survival data; (2) EV-302/KEYNOTE-B15 updated analysis: enfortumab vedotin + pembrolizumab vs. neoadjuvant cisplatin-based chemotherapy in perioperative muscle-invasive bladder cancer (Phase 3 data); (3) VIKTORIA-1: inavolisib (PI3Kα inhibitor) + palbociclib + fulvestrant in PIK3CA-mutant ER+ HER2- metastatic breast cancer; (4) CHRYSALIS-2 update: amivantamab + lazertinib in atypical EGFR-mutant NSCLC with CNS efficacy data; (5) CHALLENGE trial: structured exercise intervention post-adjuvant chemotherapy for colon cancer survivors with cost-utility analysis. ASCO 2026 also features the long-awaited Phase 3 data presentation by Revolution Medicines on daraxonrasib (RMC-6236) in metastatic pancreatic cancer at the plenary session on May 31 — a potential practice-changing readout in one of oncology's most resistant diseases. The ASCO abstract release initiates the peak oncology data cycle, with trial data entering the scientific and regulatory conversation ahead of formal presentations and potential FDA submissions.